---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-338022"
form_type: "8-K"
ticker: "ORGO"
cik: "0001661181"
company_name: "Organogenesis Holdings Inc."
filed_at: "2026-08-06T20:11:52+00:00"
generated_at: "2026-08-06T20:16:12.462763+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Organogenesis Q2 revenue down 58% to $42.8M; net loss widens to $96.3M; FY guidance slashed

## Summary
- Net revenue $42.8M vs $100.8M YoY; Advanced Wound Care fell 61% to $36.1M.
- Net loss $96.3M ($0.77/share) vs $9.4M loss ($0.10/share) in Q2 2025.
- Adjusted EBITDA loss $34.4M vs $3.6M loss; operating loss $51.0M vs $12.6M.
- FY 2026 revenue guidance cut to $179M-$215M (62-68% decline) from prior 45-52% decline.
- Cash $46.8M, no debt; CEO cites slower-than-expected market recovery.

## SEC filing metadata
- accession: 0001193125-26-338022
- form_type: 8-K
- ticker: ORGO
- cik: 0001661181
- company_name: Organogenesis Holdings Inc.
- filed_at: 2026-08-06T20:11:52+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1661181/000119312526338022/0001193125-26-338022-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1661181/000119312526338022/orgo-20260806.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-338022
- JSON: https://secwatch.observer/filing/0001193125-26-338022.json
- Plain text: https://secwatch.observer/filing/0001193125-26-338022.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.